HHS Medicare Rx Price Negotiations Would Fail For Lack Of Force, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The current Administration, as well as those in the future, would not be willing or able to enforce drug prices significantly below competitive market rates, CMS Chief Actuary Foster says in memo. Giving HHS price negotiating authority would lead to restrictions on drug choice, Administrator McClellan asserts.
You may also be interested in...
HDMA Monitoring Efforts To Repeal Medicare "Non-Interference" Clause
The Healthcare Distribution Management Association is monitoring efforts to reopen the Medicare Modernization Act to remove the clause excluding government from price negotiations, Regulatory Affairs Director Falb noted at the group's distribution management conference. HDMA has also formed a task force to develop proposals for Medicaid reform.
HDMA Monitoring Efforts To Repeal Medicare "Non-Interference" Clause
The Healthcare Distribution Management Association is monitoring efforts to reopen the Medicare Modernization Act to remove the clause excluding government from price negotiations, Regulatory Affairs Director Falb noted at the group's distribution management conference. HDMA has also formed a task force to develop proposals for Medicaid reform.
HHS Negotiating Authority Should Be Medicare Law's Only Change – Kennedy
In a letter to President Bush, Sen. Kennedy (D-Mass.) and Rep. Waxman (D-Calif.) say that giving HHS the authority to negotiate pharmaceutical prices would save $190 bil. over the next decade, with no reduction in benefits.